LEXICON PHARMACEUTICALS, INC. Proceeds from Long-Term Debt Issued
LEXICON PHARMACEUTICALS, INC. (LXRX) reported Proceeds from Long-Term Debt Issued of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfLongTermDebt · last filed 2026-03-05
- LEXICON PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2024-12-31 was $0.00.
- LEXICON PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2023-12-31 was -$1.00K, a 100.00% decline year-over-year.
- LEXICON PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for the quarter ending 2023-09-30 was $1.00K.
- LEXICON PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2025 was $0.00.
- LEXICON PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- LEXICON PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2023 was $49.96M, a 2.24% increase from fiscal 2022.
- LEXICON PHARMACEUTICALS, INC. proceeds from issuance of long-term debt for fiscal 2022 was $48.87M.
| Period end | Proceeds from Issuance of Long-term Debt 3 month | Proceeds from Issuance of Long-term Debt 6 month | Proceeds from Issuance of Long-term Debt 9 month | Proceeds from Issuance of Long-term Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-05 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $0.00 10-K · filed 2026-03-05 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-02 | |||
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $0.00 derived: sum of 2 quarters · filed 2026-03-05 | $49.96M derived: sum of 3 quarters · filed 2026-03-05 | $49.96M 10-K · filed 2026-03-05 |
| 2023-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $49.96M derived: sum of 2 quarters · filed 2024-11-13 | $49.96M 10-Q · filed 2024-11-13 | $74.93M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-06-30 | $49.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | $49.96M 10-Q · filed 2024-08-02 | $74.93M derived: sum of 3 quarters · filed 2025-03-07 | $74.68M derived: sum of 4 quarters · filed 2025-03-07 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $24.97M derived: sum of 2 quarters · filed 2025-03-07 | $24.72M derived: sum of 3 quarters · filed 2025-03-07 | $24.72M derived: sum of 4 quarters · filed 2025-03-07 |
| 2022-12-31 | $24.97M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $24.72M derived: sum of 2 quarters · filed 2025-03-07 | $24.72M derived: sum of 3 quarters · filed 2025-03-07 | $48.87M 10-K · filed 2025-03-07 |
| 2022-09-30 | -$249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$249.00K derived: sum of 2 quarters · filed 2023-11-08 | $23.90M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | $24.15M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | $24.15M 10-Q · filed 2023-05-04 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $0.00 10-Q · filed 2022-08-03 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | $0.00 10-K · filed 2021-03-12 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $0.00 10-K · filed 2021-03-12 | ||
| 2019-09-30 | $0.00 10-Q · filed 2019-11-07 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | $12.53M 10-K · filed 2021-03-12 | ||
| 2018-09-30 | $12.53M 10-Q · filed 2019-11-07 | |||
| 2017-12-31 | $145.91M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $145.91M 10-K · filed 2020-03-12 | ||
| 2017-09-30 | $0.00 10-Q · filed 2018-11-01 | |||
| 2016-12-31 | $0.00 10-K · filed 2019-03-15 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-03-01 | |||
| 2014-12-31 | $84.14M 10-K · filed 2017-03-06 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-03-11 | |||
| 2012-12-31 | $0.00 10-K · filed 2015-03-12 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $0.00 derived: sum of 2 quarters · filed 2013-03-11 | $0.00 10-K · filed 2013-03-11 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | $0.00 10-Q · filed 2011-11-01 | ||
| 2011-06-30 | $0.00 10-Q · filed 2011-08-09 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11 | $0.00 derived: sum of 2 quarters · filed 2013-03-11 | $11.38M 10-K · filed 2013-03-11 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-01 | $11.38M 10-Q · filed 2011-11-01 | ||
| 2010-06-30 | $11.38M 10-Q · filed 2011-08-09 | |||
| 2009-12-31 | $38.59M 10-K · filed 2012-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |